# A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT07123103** · PHASE1 · RECRUITING · sponsor: **Exelixis** · enrollment: 150 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** XB371

## Key facts

- **NCT ID:** NCT07123103
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2027-11
- **Final completion:** 2028-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123103, "A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07123103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*